WO2012060594A3 - Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient - Google Patents

Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient Download PDF

Info

Publication number
WO2012060594A3
WO2012060594A3 PCT/KR2011/008205 KR2011008205W WO2012060594A3 WO 2012060594 A3 WO2012060594 A3 WO 2012060594A3 KR 2011008205 W KR2011008205 W KR 2011008205W WO 2012060594 A3 WO2012060594 A3 WO 2012060594A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
thiourea compound
active ingredient
composition containing
Prior art date
Application number
PCT/KR2011/008205
Other languages
French (fr)
Korean (ko)
Other versions
WO2012060594A2 (en
Inventor
전라옥
류재하
천예진
박병현
Original Assignee
숙명여자대학교산학협력단
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 숙명여자대학교산학협력단, 전북대학교산학협력단 filed Critical 숙명여자대학교산학협력단
Publication of WO2012060594A2 publication Critical patent/WO2012060594A2/en
Publication of WO2012060594A3 publication Critical patent/WO2012060594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

【Abstract】 The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases, wherein the pharmaceutical composition contains, as an active ingredient, a thiourea compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof. The thiourea compound or pharmaceutically acceptable salt thereof, according to the present invention, reduces the activity of NF-kB that causes inflammatory diseases in a fibroblast-type synoviocyte and a mouse model of collagen induced arthritis, and effectively inhibits edema and pain. Thus, the composition of the present invention can be usefully used in preventing and treating inflammatory diseases such as rheumatoid arthritis.
PCT/KR2011/008205 2010-11-05 2011-10-31 Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient WO2012060594A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0109793 2010-11-05
KR1020100109793A KR20120048250A (en) 2010-11-05 2010-11-05 Anti-inflammatory composition containing thiourea compound or pharmaceutically acceptable salts thereof as active ingredient

Publications (2)

Publication Number Publication Date
WO2012060594A2 WO2012060594A2 (en) 2012-05-10
WO2012060594A3 true WO2012060594A3 (en) 2012-06-28

Family

ID=46024928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008205 WO2012060594A2 (en) 2010-11-05 2011-10-31 Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient

Country Status (2)

Country Link
KR (1) KR20120048250A (en)
WO (1) WO2012060594A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101639599B1 (en) * 2015-11-09 2016-07-14 서울대학교산학협력단 Peptide thiourea derivatives, their radioisotope labeled compounds and pharmaceutical composition for treatment or diagnosis of prostate cancer comprising the same as an active ingredient
CN111830254B (en) * 2020-07-29 2022-07-26 武汉生之源生物科技股份有限公司 Matrix metalloproteinase-3 determination kit and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048108A2 (en) * 2001-11-29 2003-06-12 Theracos, Inc Compounds for treatment of inflammation, diabetes and related disorders
WO2009058739A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048108A2 (en) * 2001-11-29 2003-06-12 Theracos, Inc Compounds for treatment of inflammation, diabetes and related disorders
WO2009058739A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHUN, YE JIN ET AL.: "Synthesis of Heterocycle-linked Thioureas and Their Inhibitory Activities of No Production in LPS Activated Macrophages", BULL. KOREAN CHEM. SOC., vol. 31, no. 1, 20 January 2010 (2010-01-20), pages 27 - 30 *
LEE, YR ET AL.: "SPA0355, a thiourea analogue, inhibits inflammatory responses and joint destruction in fibroblast-like synoviocytes and mice with collagen-induced arthritis", BR. J. PHARMACOL., vol. 164, September 2011 (2011-09-01), pages 794 - 806 *

Also Published As

Publication number Publication date
KR20120048250A (en) 2012-05-15
WO2012060594A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
MX2015008396A (en) 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same.
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
MY161001A (en) Tetrahydrocarboline Derivative
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
NZ602510A (en) Treatment of lupus nephritis using laquinimod
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
NZ605469A (en) Nalbuphine-based formulations and uses thereof
UA110013C2 (en) APPLICATION OF THE COMPOSITION FOR THE TREATMENT OF BALL-MARI-HERE AND THE RELATED DISORDERS
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
HRP20171742T4 (en) 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide for the treatment of migraine via the oral or intravenous route
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2013022243A3 (en) Novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising same as an active ingredient
WO2014056824A3 (en) Oral care composition
MX2012008509A (en) Therapeutic or prophylactic agent for biliary diseases.
JP2011512394A5 (en)
WO2012060594A3 (en) Anti-inflammatory composition containing a thiourea compound and a pharmaceutically acceptable salt thereof as an active ingredient
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
TN2010000120A1 (en) Galenical formulations of organic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838199

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11838199

Country of ref document: EP

Kind code of ref document: A2